Red Light Holland and Kala Bio Announce AI Engagement for Drug Development
On March 18, 2026, Red Light Holland Corp. and Kala Bio, Inc. announced that Red Light has engaged Kala Bio’s Researgency.ai platform to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp., according to GlobeNewswire PE.
Details of the Engagement
The engagement involves deploying Kala Bio’s Researgency.ai agentic artificial intelligence platform, licensed worldwide from Younet, to assist in clinical planning, protocol optimization, and scenario modeling for Red Light’s regulated drug development program for PEX010. Red Light recently announced a definitive arrangement agreement to acquire Filament’s business, including its portfolio of 76 issued patents across 15 patent families. This acquisition encompasses PEX010, which is currently supplied to more than 70 clinical research sites worldwide.
Strategic Rationale Behind the Partnership
The use of Kala Bio’s Researgency.ai platform forms a key part of Red Light’s strategy to integrate AI-driven research capabilities into its expanding regulated psychedelic drug development platform. Custom purpose-built AI agents, trained by Younet engineers in collaboration with Kala and operated under private cloud LLM infrastructure supplied by Kala, aim to accelerate research planning, scenario simulation, and protocol optimization for advancing PEX010. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at institutions such as Johns Hopkins University and Dana-Farber Cancer Institute, according to GlobeNewswire PE.
Overview of PEX010 and Its Development Status
PEX010 has received authorization from Health Canada and the U.S. Food and Drug Administration for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder. This drug candidate is one of the most widely studied botanical psilocybin options in regulated clinical research, with programs from other companies like Compass Pathways and AtaiBeckley also advancing similar candidates. As a widely known context, psilocybin research has gained attention in mental health treatments, though this engagement specifically focuses on enhancing Red Light’s development efforts.
